Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effectiveness and safety of Chinese Patent Medicines based on syndrome differentiation in patients following percutaneous coronary intervention due to acute coronary syndrome (CPM trial): A nationwide Cohort Study.
Bai R, Yang Q, Xi R, Che Q, Zhao Y, Guo M, Dong G, Gao Z, Fu C, Wang P, Gu F, Du J, Zhang D, Duan W, Li L, Shi D. Bai R, et al. Among authors: duan w. Phytomedicine. 2023 Jan;109:154554. doi: 10.1016/j.phymed.2022.154554. Epub 2022 Nov 19. Phytomedicine. 2023. PMID: 36610159 Free article. Clinical Trial.
Combination of Activating Blood Circulation and Detoxifying Chinese Medicines Played an Anti-Inflammatory Role in Unstable Angina Patients after Percutaneous Coronary Intervention: A Multicenter, Open-Labeled, Randomized Controlled Trial.
Ma XJ, Duan WH, Zhang Y, Gao J, Guan BY, Chen KJ, Shi DZ. Ma XJ, et al. Chin J Integr Med. 2021 Nov;27(11):803-810. doi: 10.1007/s11655-021-2878-8. Epub 2021 Sep 16. Chin J Integr Med. 2021. PMID: 34532749 Clinical Trial.
P2y12 inhibitor monotherapy after 1-3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
Yu Y, Pan D, Bai R, Luo J, Tan Y, Duan W, Shi D. Yu Y, et al. Among authors: duan w. Front Cardiovasc Med. 2023 Jul 6;10:1197161. doi: 10.3389/fcvm.2023.1197161. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37485257 Free PMC article. Review.
Quanduzhong capsules for the treatment of grade 1 hypertension patients with low-to-moderate risk: A multicenter, randomized, double-blind, placebo-controlled clinical trial.
Xu X, Tian W, Duan W, Pan C, Huang M, Wang Q, Yang Q, Wen Z, Tang Y, Xiong Y, Zhu Z, Liu Y, Wei D, Qi W, Ouyang X, Ying S, Wang X, Zhou Z, Li X, Cui Y, Yang S, Xu H. Xu X, et al. Among authors: duan w. Front Pharmacol. 2023 Jan 10;13:1014410. doi: 10.3389/fphar.2022.1014410. eCollection 2022. Front Pharmacol. 2023. PMID: 36703729 Free PMC article.
Chirality-Dependent Dynamic Evolution for Trions in Monolayer WS2.
Xiang B, Wang R, Chen Y, Wang Y, Qin T, Zhang M, Watanabe K, Taniguchi T, Duan W, Tang P, Liu H, Xiong Q. Xiang B, et al. Among authors: duan w. Nano Lett. 2024 May 24. doi: 10.1021/acs.nanolett.4c01082. Online ahead of print. Nano Lett. 2024. PMID: 38787539
3,226 results